However, blocking the BAFF–BAFFR pathway alone may not be as forcefully effective as pan-B cell depletion therapies, given the fact that Belimumab depletes B cells through BAFF neutralization, and only achieved modest efficacy in some SLE patients in randomized clinical trials [10]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.